Our Immune Signature Tests are based on RNA biomarker signatures obtained from a specific population of immune cells, a fraction of leukocytes. Our tests are based on the reaction of the immune system to malignant growth, which occurs long before clinical manifestation.
For the detection of ovarian cancer in high-risk patient groups, a combination of RNA and protein biomarkers is currently investigated. The oustanding uniqueness of this approach is the integration of both, RNA expression biomarkers from specific cells of the immune system and serum protein biomarkers, into one diagnostic model.
Regarding the detection of breast cancer, RNA biomarkers are perfectly adequate to discriminate breast cancer patients from healthy females. The RNA breast cancer test will be mainly used in case of an unclear mammography result to ascertain if the woman suffers from breast cancer or not.
Our Immune Signature Tests will be provided for ovarian cancer, breast cancer, colorectal cancer, prostate cancer, and pancreatic cancer.